Vivendy makes management and board changes
This article was originally published in Scrip
Vivendy Therapeutics(Switzerland) has announced that its chief executive officer, Dr Roland Toder, is stepping down on September 30th. Vivendy has nominated Dr Gosse Bruinsma to its board, and anticipates that this nomination will be ratified at the company's next shareholder meeting. Dr Bruinsma, who most recently served as executive chairman at Curidium Medica, will also assume an executive function, which will encompass the activities of the CEO.
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).